Abatacept for GVHD prophylaxis can reduce racial disparities by abrogating the impact of mismatching in unrelated donor stem cell transplantation

Supplement Table 1. Baseline Characteristics of 7/8 matched unrelated donor +Abatacept group (MMUD/aba) and 8/8 matched unrelated donor group (MUD/Placebo)

Characteristic	MMUD/aba N=43	MUD/Placebo N=69	P-value
Mean Age at Transplant (years)	36.3 (SD 22.9)	40.4 (20.3)	0.328
Race			
Caucasian	30 (69.8%)	61 (88.4%)	0.087
African American	7 (16.3%)	4 (5.8%)	
Asian	2 (4.6%)	2 (2.9%)	
Unknown	4 (9.3%)	2 (2.9%)	
Performance Score			
90-100%	32 (74.4%)	52 (75.4%)	0.911
<90%	11 (25.6%)	17 (24.6%)	
Diagnosis			
AML	15 (34.9%)	22 (31.9%)	0.505
ALL	9 (20.9%)	23 (33.3%)	
CML/HL/Other	8 (18.6%)	12 (17.4%)	
MDS	11 (25.6%)	12 (17.4%)	
CIBMTR Disease Stage			
Early	26 (60.5%)	36 (52.2%)	0.690
Intermediate	10 (23.3%)	19 (27.5%)	
Advanced	7 (16.3%)	14 (20.3%)	
Conditioning Regimen			
Busulfan/Fludarabine	8 (18.6%)	2 (2.9%)	0.035
Busulfan/ Cyclophosphamide	13 (30.2%)	21 (30.4%)	
Total Body Irradiation/Cyclophosphamide	11 (25.6%)	26 (37.7%)	
Fludarabine/Melphalan	11 (25.6%)	20 (29%)	
Conditioning Intensity			
Myeloablative	33 (76.7%)	49 (71%)	0.506
Reduced Intensity	10 (23.3%)	20 (29%)	
Graft Type			
Bone Marrow	21 (48.8%)	26 (37.7%)	0.245
PBSC	22 (51.2%)	43 (62.3%)	

Abbreviations: AML, acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myelogenous leukemia; HL, Hodgkin lymphoma; MDS, myelodysplastic syndrome; PBSC, peripheral blood stem cells